Rothblatt Martine A's Form 4 filing
United Therapeutics Corp (UTHR) · filed Oct 27, 2025
- Accession no.
- 0001106578-25-000023
- Filed
- Oct 27, 2025
- Trade date
- Oct 23-24, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 8 non-derivative transactions and 2 derivative transactions. Open-market sales total $3.39M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rothblatt Martine ACIK 0001106578 | Director, Officer (Chairperson & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 23, 2025 | Common Stock | MOption exerciseAcquired | +4,000 | $120.26 | +$481,040 | 4,130 | Direct | |
| Oct 23, 2025 | Common Stock | SSaleDisposed | −2,500 | $421.63F2 | −$1,054,075 | 1,630 | Direct | |
| Oct 23, 2025 | Common Stock | SSaleDisposed | −1,000 | $422.58 | −$422,580 | 630 | Direct | |
| Oct 23, 2025 | Common Stock | SSaleDisposed | −500 | $424.16 | −$212,080 | 130 | Direct | |
| Oct 24, 2025 | Common Stock | MOption exerciseAcquired | +4,000 | $120.26 | +$481,040 | 4,130 | Direct | |
| Oct 24, 2025 | Common Stock | SSaleDisposed | −2,937 | $423.56F3 | −$1,243,995.72 | 1,193 | Direct | |
| Oct 24, 2025 | Common Stock | SSaleDisposed | −563 | $424.64F4 | −$239,072.32 | 630 | Direct | |
| Oct 24, 2025 | Common Stock | SSaleDisposed | −500 | $426.40 | −$213,200 | 130 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 23, 2025 | Common Stock | MOption exerciseDisposed | −4,000 | $0.00 | $0 | 158,000 | Direct | |
| Oct 24, 2025 | Common Stock | MOption exerciseDisposed | −4,000 | $0.00 | $0 | 154,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $421.37 to $421.995. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $423.015 to $424.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $424.19 to $424.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.